FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366270321> ?p ?o ?g. }

• W4366270321 abstract "According to the World Health Organization, cataract operations are performed on one million people per year [1]. After cataract surgery, however, most patients still experience physiologically severe postoperative ocular inflammation. Uncontrolled intraocular inflammation causes discomfort, delayed recovery, poor visual results, and even more severe problems such as cystoid macular oedema and synechiae due to inflammatory cells and cytokines entering the aqueous humour. Topical non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat non-infectious ocular inflammation after ophthalmic surgery. As a result, NSAIDs appear to be potentially useful drugs for cataract surgery. [2] The U.S Food and Drug Administration has approved four ophthalmic NSAIDs to treat postoperative ocular inflammation followed by cataract surgery: bromfenac sodium, diclofenac sodium, Ketorolac tromethamine, and nepafenac.[3] The first approved NSAID for treating anterior chamber inflammation during cataract surgical treatment is bromfenac ophthalmic solution. Bromfenac is a more potent drug than other drugs for treating ocular inflammation. [4] The drug-loaded eye drop is easy to use. However, it has the inherent disadvantage that most medication is almost immediately diluted away in the tear film when the eye drops are introduced into the cul-de-sac and quickly exhausted from the precorneal cavity's constant tear flow. This process occurs more intensively in swollen eyes than in normal eyes and lachrymal-nasal drainage. [5,6] To avoid the previously stated side effects and increase the drug's effectiveness, a novel approach of an ocular insert that increases the drug's contact time in the eye should be chosen, thus improving patient compliance by increasing bioavailability and reducing frequent administration. [7] Ophthalmic inserts are skinny discs of polymeric substances that fit into the upper or lower conjunctiva sac. They have compensations over the conventional dosage forms and possess amplified ocular residence, discharge the drugs at a slow and consistent momentum, are capable of delivering precise dosing, lack preservatives, have augmented shelf life, and reduced systemic incorporation. [8] Our research intended to fabricate bromfenac sodium ocular inserts to amplify the contact time and offer a controlled release model that could advance patient compliance, cut dosing frequency, and attain superior curative usefulness." @default.
• W4366270321 created "2023-04-20" @default.
• W4366270321 creator A5024131383 @default.
• W4366270321 creator A5025246517 @default.
• W4366270321 creator A5036091980 @default.
• W4366270321 creator A5061709416 @default.
• W4366270321 creator A5071348484 @default.
• W4366270321 creator A5078094933 @default.
• W4366270321 date "2023-04-18" @default.
• W4366270321 modified "2023-10-18" @default.
• W4366270321 title "Formulation And Evaluation of Controlled Release Bromfenac Sodium Ocular Insert" @default.
• W4366270321 cites W1974924127 @default.
• W4366270321 cites W1985166893 @default.
• W4366270321 cites W2015117635 @default.
• W4366270321 cites W2058071095 @default.
• W4366270321 cites W2089650197 @default.
• W4366270321 cites W2095368030 @default.
• W4366270321 cites W2098771451 @default.
• W4366270321 cites W2145357764 @default.
• W4366270321 cites W2160186005 @default.
• W4366270321 cites W2257539576 @default.
• W4366270321 cites W2593673438 @default.
• W4366270321 doi "https://doi.org/10.37521/ejpps.28102" @default.
• W4366270321 hasPublicationYear "2023" @default.
• W4366270321 type Work @default.
• W4366270321 citedByCount "0" @default.
• W4366270321 crossrefType "journal-article" @default.
• W4366270321 hasAuthorship W4366270321A5024131383 @default.
• W4366270321 hasAuthorship W4366270321A5025246517 @default.
• W4366270321 hasAuthorship W4366270321A5036091980 @default.
• W4366270321 hasAuthorship W4366270321A5061709416 @default.
• W4366270321 hasAuthorship W4366270321A5071348484 @default.
• W4366270321 hasAuthorship W4366270321A5078094933 @default.
• W4366270321 hasBestOaLocation W43662703211 @default.
• W4366270321 hasConcept C118487528 @default.
• W4366270321 hasConcept C141071460 @default.
• W4366270321 hasConcept C2775888743 @default.
• W4366270321 hasConcept C2777625524 @default.
• W4366270321 hasConcept C2777917749 @default.
• W4366270321 hasConcept C2778446825 @default.
• W4366270321 hasConcept C2780035454 @default.
• W4366270321 hasConcept C2780820201 @default.
• W4366270321 hasConcept C2908765736 @default.
• W4366270321 hasConcept C2909274023 @default.
• W4366270321 hasConcept C42219234 @default.
• W4366270321 hasConcept C71924100 @default.
• W4366270321 hasConcept C98274493 @default.
• W4366270321 hasConceptScore W4366270321C118487528 @default.
• W4366270321 hasConceptScore W4366270321C141071460 @default.
• W4366270321 hasConceptScore W4366270321C2775888743 @default.
• W4366270321 hasConceptScore W4366270321C2777625524 @default.
• W4366270321 hasConceptScore W4366270321C2777917749 @default.
• W4366270321 hasConceptScore W4366270321C2778446825 @default.
• W4366270321 hasConceptScore W4366270321C2780035454 @default.
• W4366270321 hasConceptScore W4366270321C2780820201 @default.
• W4366270321 hasConceptScore W4366270321C2908765736 @default.
• W4366270321 hasConceptScore W4366270321C2909274023 @default.
• W4366270321 hasConceptScore W4366270321C42219234 @default.
• W4366270321 hasConceptScore W4366270321C71924100 @default.
• W4366270321 hasConceptScore W4366270321C98274493 @default.
• W4366270321 hasLocation W43662703211 @default.
• W4366270321 hasOpenAccess W4366270321 @default.
• W4366270321 hasPrimaryLocation W43662703211 @default.
• W4366270321 hasRelatedWork W1988440334 @default.
• W4366270321 hasRelatedWork W1996390384 @default.
• W4366270321 hasRelatedWork W2005852535 @default.
• W4366270321 hasRelatedWork W2037560348 @default.
• W4366270321 hasRelatedWork W2066310088 @default.
• W4366270321 hasRelatedWork W2075149323 @default.
• W4366270321 hasRelatedWork W2094354059 @default.
• W4366270321 hasRelatedWork W2262554958 @default.
• W4366270321 hasRelatedWork W2414834292 @default.
• W4366270321 hasRelatedWork W4366270321 @default.
• W4366270321 isParatext "false" @default.
• W4366270321 isRetracted "false" @default.
• W4366270321 workType "article" @default.